General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination

Current Gene Therapy

Volumn 13, Issue 6, 2013, Pages 385-394

  Baldo, Aline ^a   van den Akker, Eric ^b   Bergmans, Hans E ^b   Lim, Filip ^c   Pauwels, Katia ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Biosafety; Environmental risk assessment; Gene therapy; Genetically modified organisms; Vaccination; Viral vectors

Indexed keywords

BIOLOGICAL FACTOR; VIRUS VECTOR;

ARTICLE; BIOSAFETY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; HAZARD ASSESSMENT; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; NONHUMAN; RISK ASSESSMENT; RISK MANAGEMENT; TRANSGENE; TRANSGENIC ORGANISM; VACCINATION; VIRAL GENE THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HAZARDOUS SUBSTANCES; HUMANS; ORGANISMS, GENETICALLY MODIFIED; RISK ASSESSMENT; VACCINATION; VIRUSES;

EID: 84891752685     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113136660005     Document Type: Article

References (39)

1. Bleijs DA, Haenen ITWC., Bergmans JEN. Gene therapy legislation in the Netherlands. J Gene Med 2007; 9: 904-9.
2. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J 01.05.2001; L121:34.
3. Directive 2001/18/EC of the European parliament and of the Council of 12 March on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Off J 17.04.2001; L106:1.
4. Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 march 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J 30.04.2004; L136:1.
5. Directive 2009/41/EC of the European Parliament and of the council of 6 May 2009 on the contained use of genetically modified micro-organisms (Recast). Off J 21.05.2009; L125:0075.
6. Linkov I, Loney D, Cormier S, Satterstrom FK, Bridges T. Weightof-evidence evaluation in environmental assessment: Review of qualitative and quantitative approaches. Sci Total Environ 2009; 407(19): 5199-205.
7. van den Akker E, van der Vlugt CJB, Bergmans HEN. Environmental risk assessment of replication competent viral vectors applied in gene therapy: potential effects of inserted sequences. Curr Gene Ther 2013, 13, 413-20.
8. Goossens M, Pauwels K, Willemarck N, Breyer D. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors. Curr Gene Ther 2013, 13, in press.
9. EC Commission Decision 2002/623/EC of 24 July 2002 establishing guidance notes supplementing Annex II to Directive 2001/18/EC of the European Parliament and of the Council on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Off J Eur Commun, L200 of 30.07.2002.
10. Communication from the commission on the precautionary principle COM (2000)1. [online] 2001. [cited 02/09/2013] Available at http://ec.europa.eu/dgs/health_consumer/library/pub/pub07_en.pdf
11. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9(10): 910-21.
12. Committee for the medicinal product for human use (CHMP). Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. EMA. [online] 2007. [cited 02/09/2013] Available at: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/09/WC500003 964.pdf
13. Hill RA. Conceptualizing risk assessment methodology for genetically modified organisms. Environ Biosafety Res 2005; 4, 67-70.
14. rd ed). Geneva: WHO. [online] 2004 [cited 02/09/2013]. Available at: http://www.who.int/csr/resources/publications/biosafety/ en/Biosafety7.pdf
15. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9(13): 1909-17.
16. Pauwels K, Gijsbers R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009; 9(6): 459-74.
17. Schambach A, Zychlinski D, Ehrnstroem B, Baum C. Biosafety featured of lentiviral vectors. Hum Gene Ther 2013; 24(2): 132-42.
18. Rothe M, Modlich U, Schambach A. Biosafety challenges for use of lentiviral vectors. Curr Gene Ther 2013; 13, in press.
19. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther 2013; 13, in press.
20. Xiao X, Li J, Samulski RJ. Production of a high titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72(3): 2224-32.
21. van den Akker HCM. Environmental risk assessment of replication competent viral vectors in gene therapy trials. RIVM. [online] 2008 [cited 02/09/2013] Available at: http://rivm.nl/bibliotheek/ rapporten/ 601850001.pdf
22. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61(7-8): 554-71.
23. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002; 9(12), 1022-35.
24. Wold WSM, Toth K. Adenovirus vectors for gene therapy and cancer gene therapy. Curr Gene Ther 2013; 13, in press.
25. Carson J, Haddad D, Bressman M, Fong Y. Oncolytic herpes simplex virus 1 (HSV-1) vectors: increasing treatment efficacy and range through strategic virus design. Drugs Future 2010; 35(3), 183-95.
26. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 2013; 161(4): 355-64.
27. Lim F, Khalique H, Ventosa M, Baldo A. Biosafety of gene therapy vectors derived from Herpes Simplex Virus Type 1. Curr Gene Ther 2013; 13, in press.
28. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001; 38(3): 177-92.
29. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gen Ther 2006; 13(9): 830-44.
30. Zeyaullah Md., Patro M, Ahmad I, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012; 18(4): 771-81.
31. Rojas JJ, Guedan S, Searle PF, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgenearming capacity in oncolytic adenoviruses. Mol Ther 2010, 18(11): 1960-71.
32. Manservigi R, Argnani R, Marconi P. HSV recombinant vectors for gene therapy. Open Virol J 2010; 4: 123-56.
33. Gabriel R, Schmidt M, von Kalle C. Integration of retroviral vectors. Curr Opin Immunol 2012; 24(5): 592-97.
34. Deichmann A, Schmidt M. Biosafety considerations using gammaretroviral vectors in gene therapy. Curr Gene Ther 2013; 13, in press.
35. Janovitz T, Klein IA, Oliveira T, et al. High-throughput sequencing reveals principles of adeno-associated Virus serotype 2 integration. J Virol 2013; 87(15):8559-68.
36. Hoeben RC, Louz D, Koppers-Lalic D. Biosafety of non-human therapeutic viruses in clinical gene therapy. Curr Gene Ther 2013; 13, in press.
37. Bergmans H, Logie C, van Maanen K, Hermsen H, Meredyth M, van der Vlugt C. Identification of potentially hazardous human gene products in GMO risk assessment. Environ Biosafety Res 2008; 7, 1-9.
38. Gogev S, Schynts F, Meurens F, Bourgot I, Thiry E. Biosafety of Herpesvirus vectors. Curr Gene Ther 2003; 3(6): 597-611.
39. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse Interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75(3): 1205-10.